Stockscreener 앱 받기
200.87
1.40%
-2.86
시간 외 거래:
200.87
전일 마감가:
$203.73
열려 있는:
$201.63
하루 거래량:
586.97K
Relative Volume:
0.58
시가총액:
$13.91B
수익:
$2.71B
순이익/손실:
$247.10M
주가수익비율:
57.38
EPS:
3.5008
순현금흐름:
$349.90M
1주 성능:
+1.55%
1개월 성능:
-11.55%
6개월 성능:
-38.54%
1년 성능:
-18.61%
1일 변동 폭
$199.78
$204.95
1주일 범위
$198.80
$205.95
52주 변동 폭
$194.61
$354.88
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corp
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
200.87 | 14.11B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2026-01-27 | 재개 | TD Cowen | Hold |
| 2026-01-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-12-16 | 개시 | Evercore ISI | Outperform |
| 2025-11-19 | 업그레이드 | UBS | Neutral → Buy |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 재개 | Oppenheimer | Outperform |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-05-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
Is Insulet Corporation (PODD) One of the Most Oversold Healthcare Stocks to Invest In? - Yahoo Finance
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should You Investigate Insulet Corporation (NASDAQ:PODD) At US$204? - 富途牛牛
Insulet Taps Mike Panos As CCO While Shares Trade Below Targets - Yahoo Finance
Analysts see 75% upside on Insulet Corporation (PODD) despite weak share price momentum - MSN
Insulet Corp stock (US45784P1012): Is tubeless insulin delivery strong enough to unlock new upside? - AD HOC NEWS
Insulet stock (US45784P1012): Is the Omnipod edge strong enough to unlock new upside? - AD HOC NEWS
Short Interest in Insulet Corporation (NASDAQ:PODD) Rises By 19.3% - MarketBeat
Insulet Corp. stock rises Friday, still underperforms market - MarketWatch
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN
Insulet Corporation Appoints Mike Panos as Chief Commercial Officer - HarianBasis.co
Citi Flags Competitive Pressure as Key Risk for Insulet Corporation (PODD) - Yahoo Finance
Insulet Corp. Stock Hits 52-Week Low at USD 197.63 Amid Challenges - Markets Mojo
KBC Group NV Grows Stock Position in Insulet Corporation $PODD - MarketBeat
Lbp Am Sa Grows Position in Insulet Corporation $PODD - MarketBeat
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - ChartMill
PODD Investor Alert: Insulet Corp. Potential Securities - GlobeNewswire
Insulet Faces Omnipod 5 Correction While Shares Trade Below Targets - Sahm
BTIG Maintains Buy Rating on Insulet (PODD) - Insider Monkey
Truist Financial Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price - MarketBeat
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky - Morningstar
Truist Cuts Price Target on Insulet to $315 From $360, Keeps Buy Rating - marketscreener.com
Patton Fund Management Inc. Reduces Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Evercore Reiterates Outperform Rating for Insulet Corp. (PODD) - Insider Monkey
RBC Cuts Price Target on Insulet to $325 From $380, Keeps Outperform Rating - marketscreener.com
Insulet (NASDAQ:PODD) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
BTIG Research Lowers Insulet (NASDAQ:PODD) Price Target to $320.00 - MarketBeat
BTIG Maintains Insulet(PODD.US) With Buy Rating, Cuts Target Price to $320 - Moomoo
BTIG Research Adjusts Insulet Price Target to $320 From $380, Maintains Buy Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Increases Stock Position in Insulet Corporation $PODD - MarketBeat
Baillie Gifford & Co. Trims Stock Position in Insulet Corporation $PODD - MarketBeat
A Look At Insulet (PODD) Valuation After Mike Panos Joins As Chief Commercial Officer - Sahm
Liquidity Mapping Around (PODD) Price Events - Stock Traders Daily
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer - MSN
Insulet Corp. stock falls to new 52-week low - MarketWatch
Insulet stock (US45784P1012): Is its tubeless insulin tech strong enough to unlock new upside? - AD HOC NEWS
New Commercial Chief and Closed-Loop Progress Might Change The Case For Investing In Insulet (PODD) - Sahm
Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth - Yahoo Finance Australia
A Look At Insulet (PODD) Valuation After Recent Share Price Weakness - Yahoo Finance
Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum - Insider Monkey
Insulet stock: What investors need to know amid diabetes tech boom - AD HOC NEWS
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Insulet Corp. Hits 52-Week Low at USD 199.53 Amid Market Challenges - Markets Mojo
Goldman Sachs Adjusts Price Target on Insulet to $277 From $326, Maintains Buy Rating - marketscreener.com
Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insulet Corporation stock hits 52-week low at 199.53 USD By Investing.com - Investing.com Australia
Insulet Corporation (PODD) Stock forecasts - Yahoo Finance UK
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.72%
자본화:
|
볼륨(24시간):